BACKGROUND: The presence of human papillomavirus (HPV)-specific antibodies in patients with head and neck cancer at enrollment has prognostic significance. In cervical carcinoma patients, the decrease of HPV E6/E7-specific antibodies appears to be associated with a better prognosis. METHODS: This prospective study with follow-up focused on the persistence and prognostic value of antibodies specific for HR HPV-derived VLPs and HPV16 E6/E7 oncoproteins in patients with oropharyngeal cancers. In this study, we analyzed sera of 93 patients taken a year after the end of treatment and sera from 58 of these patients taken up to 14 years after treatment. RESULTS: The level of HPV-specific antibodies decreased on the 1-year follow-up and the decrease during the long follow-up was statistically significant. For HPV16 E7 antibodies the decrease was steeper in nonrecurrent patients. While the level of antibodies at enrollment was not predictive of recurrences, the decrease of HPV16 E6 antibodies at 1-year follow up was associated with better overall as well as disease-specific survival of patients. CONCLUSIONS: The data suggest that the pretreatment level of HPV-specific antibodies is not predictive of the occurrence of recurrences but the decrease HPV16 E6 antibodies on the 1-year follow-up is predictive of better survival of HN patients.

Department of Genetics and Microbiology Faculty of Science Charles University BIOCEV Průmyslová Vestec Czech Republic

Department of Immunology Institute of Hematology and Blood Transfusion Prague Czech Republic

Department of Mathematical Analysis and Applications of Mathematics Faculty of Science of the Palacky University in Olomouc Olomouc Czech Republic

Department of Otorhinolaryngology and Head and Neck Surgery 1st Faculty of Medicine Charles University Motol University Hospital Prague Czech Republic

Department of Otorhinolaryngology and Head and Neck Surgery 1st Faculty of Medicine Charles University Motol University Hospital Prague Czech Republic Department of Immunology Institute of Hematology and Blood Transfusion Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc19034627

003      

CZ-PrNML

005      

20191015104619.0

007      

ta

008      

191007s2019 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1002/jso.25473 $2 doi

035    __

$a (PubMed)30986340

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Simonidesova, Simona $u Department of Otorhinolaryngology and Head and Neck Surgery, First Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic. Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.

245    10

$a Prognostic value of posttreatment HPV-specific antibodies in patients with oropharyngeal tumors / $c S. Simonidesova, E. Hamsikova, V. Ludvikova, J. Klozar, O. Vencalek, R. Tachezy,

520    9_

$a BACKGROUND: The presence of human papillomavirus (HPV)-specific antibodies in patients with head and neck cancer at enrollment has prognostic significance. In cervical carcinoma patients, the decrease of HPV E6/E7-specific antibodies appears to be associated with a better prognosis. METHODS: This prospective study with follow-up focused on the persistence and prognostic value of antibodies specific for HR HPV-derived VLPs and HPV16 E6/E7 oncoproteins in patients with oropharyngeal cancers. In this study, we analyzed sera of 93 patients taken a year after the end of treatment and sera from 58 of these patients taken up to 14 years after treatment. RESULTS: The level of HPV-specific antibodies decreased on the 1-year follow-up and the decrease during the long follow-up was statistically significant. For HPV16 E7 antibodies the decrease was steeper in nonrecurrent patients. While the level of antibodies at enrollment was not predictive of recurrences, the decrease of HPV16 E6 antibodies at 1-year follow up was associated with better overall as well as disease-specific survival of patients. CONCLUSIONS: The data suggest that the pretreatment level of HPV-specific antibodies is not predictive of the occurrence of recurrences but the decrease HPV16 E6 antibodies on the 1-year follow-up is predictive of better survival of HN patients.

650    _2

$a protilátky virové $x krev $7 D000914

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a následné studie $7 D005500

650    _2

$a lidský papilomavirus 16 $x imunologie $7 D052162

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a skvamocelulární nádory $x krev $x mortalita $x terapie $7 D018307

650    _2

$a onkogenní proteiny virové $x imunologie $7 D009856

650    _2

$a nádory orofaryngu $x krev $x mortalita $x terapie $7 D009959

650    _2

$a Papillomavirus E7 - proteiny $x imunologie $7 D050725

650    _2

$a prediktivní hodnota testů $7 D011237

650    _2

$a prognóza $7 D011379

650    _2

$a prospektivní studie $7 D011446

650    _2

$a represorové proteiny $x imunologie $7 D012097

650    _2

$a míra přežití $7 D015996

650    _2

$a časové faktory $7 D013997

655    _2

$a časopisecké články $7 D016428

700    1_

$a Hamsikova, Eva $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.

700    1_

$a Ludvikova, Viera $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.

700    1_

$a Klozar, Jan $u Department of Otorhinolaryngology and Head and Neck Surgery, First Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.

700    1_

$a Vencalek, Ondrej $u Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science of the Palacky University in Olomouc, Olomouc, Czech Republic.

700    1_

$a Tachezy, Ruth $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Průmyslová, Vestec, Czech Republic.

773    0_

$w MED00010662 $t Journal of surgical oncology $x 1096-9098 $g Roč. 120, č. 2 (2019), s. 117-124

856    41

$u https://pubmed.ncbi.nlm.nih.gov/30986340 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20191007 $b ABA008

991    __

$a 20191015105044 $b ABA008

999    __

$a ok $b bmc $g 1451287 $s 1073177

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $b 120 $c 2 $d 117-124 $e 20190415 $i 1096-9098 $m Journal of surgical oncology $n J Surg Oncol $x MED00010662

GRA    __

$a CZ.1.05/1.1.00/02.0109 $p Ministry of Education, Youth and Sports of the Czech Republic

GRA    __

$a No. LQ1604 (Project BIOCEV-FAR) $p Ministry of Education, Youth and Sports of the Czech Republic

GRA    __

$a #17-28055A $p Czech Health Research Council of the Ministry of Health of the Czech Republic

GRA    __

$a GAUK 114216 $p Granting Agency of Charles University in Prague

LZP    __

$a Pubmed-20191007